J Clin Neurol.  2018 Jan;14(1):8-15. 10.3988/jcn.2018.14.1.8.

A Survey of the Neuro-Oncology Landscape

• Lukas RV
• Wu J
• Dey M
• Buerki RA
• Byrne RW
• Dohrmann G

• KMID: 2399593
• DOI: http://doi.org/10.3988/jcn.2018.14.1.8

Abstract

The field of neuro-oncology is evolving rapidly. Many important advances have recently been reported, and other promising investigations have the potential to soon make substantial impacts in the field, especially in the areas of high-grade gliomas and brain metastases. We present an overview of the current status of this field, highlighting the key recent advances as well as representative work of key clinical investigations, since these concepts have the potential to influence clinical management if they are demonstrated to be safe and efficacious. This overview includes some work that has only appeared in abstract form in order to provide a timely understanding of how the field is actively changing and what may lie on the horizon. We focus on both medical and surgical neuro-oncology advances in this highly multidisciplinary subspecialty.

Keyword

neuro-oncology; neurosurgery; brain metastases; glioma; viral therapy; gene therapy; laser ablation; isocitrate dehydrogenase; tumor treating fields

MeSH Terms

Brain
Genetic Therapy
Glioma
Isocitrate Dehydrogenase
Laser Therapy
Neoplasm Metastasis
Neurosurgery
Isocitrate Dehydrogenase

Figure

• 

  Fig. 1 Arrays for TTF applied directly to the shaved scalp. The patient consented to the use of this photograph. TTF: tumor treating fields.

Reference

1. Lukas RV, Gabikian P, Garza M, Chmura SJ. Treatment of brain metastases. Oncology. 2014; 87:321–329. PMID: 25227433.

2. Lukas RV, Mrugala MM. Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice. Neuro-Oncol Pract. 2016; DOI: 10.1093/nop/npw016.

3. Desjardins A, Vlahovic G, Friedman HS. Vaccine therapy, oncolytic viruses, and gliomas. Oncology (Williston Park). 2016; 30:211–218. PMID: 26984213.

4. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990; 322:494–500. PMID: 2405271.

5. Coburger J, Musahl C, Henkes H, Horvath-Rizea D, Bittl M, Weissbach C, et al. Comparison of navigated transcranial magnetic stimulation and functional magnetic resonance imaging for preoperative mapping in rolandic tumor surgery. Neurosurg Rev. 2013; 36:65–75. discussion 75-76. PMID: 22886323.

6. Nimsky C, Bauer M, Carl B. Merits and limits of tractography techniques for the uninitiated. Adv Tech Stand Neurosurg. 2016; (43):37–60. PMID: 26508405.

7. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015; 5:1164–1177. PMID: 26410082.

8. Missios S, Bekelis K, Barnett GH. Renaissance of laser interstitial thermal ablation. Neurosurg Focus. 2015; 38:E13.

9. Sharma M, Balasubramanian S, Silva D, Barnett GH, Mohammadi AM. Laser interstitial thermal therapy in the management of brain metastasis and radiation necrosis after radiosurgery: an overview. Expert Rev Neurother. 2016; 16:223–232. PMID: 26731270.

10. Patel P, Patel NV, Danish SF. Intracranial MR-guided laser-induced thermal therapy: single-center experience with the Visualase thermal therapy system. J Neurosurg. 2016; 125:853–860. PMID: 26722845.

11. Carpentier A, McNichols RJ, Stafford RJ, Guichard JP, Reizine D, Delaloge S, et al. Laser thermal therapy: real-time MRI-guided and computer-controlled procedures for metastatic brain tumors. Lasers Surg Med. 2011; 43:943–950. PMID: 22109661.

12. Ivan ME, Mohammadi AM, De Deugd N, Reyes J, Rodriguez G, Shah A, et al. Laser ablation of newly diagnosed malignant gliomas: a meta-analysis. Neurosurgery. 2016; 79(Suppl 1):S17–S23. PMID: 27861322.

13. Lee I, Kalkanis S, Hadjipanayis CG. Stereotactic laser interstitial thermal therapy for recurrent high-grade gliomas. Neurosurgery. 2016; 79(Suppl 1):S24–S34. PMID: 27861323.

14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO Classification of Tumours of the Central Nervous System WHO/IARC Classification of Tumours. 4th rev. ed. Lyon: International Agency for Research on Cancer;2016.

15. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131:803–820. PMID: 27157931.

16. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009; 462:739–744. PMID: 19935646.

17. Zhao S, Lin Y, Xu W, Jiang W, Zha Z, Wang P, et al. Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α. Science. 2009; 324:261–265. PMID: 19359588.

18. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Ann Oncol. 2016; 27:599–608. PMID: 27005468.

19. Frezza C, Tennant DA, Gottlieb E. IDH1 mutations in gliomas: when an enzyme loses its grip. Cancer Cell. 2010; 17:7–9. PMID: 20129244.

20. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009; 27:4150–4154. PMID: 19636000.

21. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell. 2012; 22:425–437. PMID: 23079654.

22. Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell. 2016; 164:550–563. PMID: 26824661.

23. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009; 360:765–773. PMID: 19228619.

24. Chen H, Judkins J, Thomas C, Wu M, Khoury L, Benjamin CG, et al. Mutant IDH1 and seizures in patients with glioma. Neurology. 2017; 88:1805–1813. PMID: 28404805.

25. Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro Oncol. 2011; 13:1339–1348. PMID: 21914639.

26. Napolitano M, Vaz G, Lawson TM, Docquier MA, van Maanen A, Duprez T, et al. Glioblastoma surgery with and without intraoperative MRI at 3.0T. Neurochirurgie. 2014; 60:143–150. PMID: 24975207.

27. Herrera SR, Shin JH, Chan M, Kouloumberis P, Goellner E, Slavin KV. Use of transparent plastic tubular retractor in surgery for deep brain lesions: a case series. Surg Technol Int. 2010; 19:47–50. PMID: 20437344.

28. Recinos PF, Raza SM, Jallo GI, Recinos VR. Use of a minimally invasive tubular retraction system for deep-seated tumors in pediatric patients. J Neurosurg Pediatr. 2011; 7:516–521. PMID: 21529192.

29. Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, et al. Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial. Neuro Oncol. 2014; 16:274–279. PMID: 24335700.

30. Lawler SE, Speranza MC, Cho CF, Chiocca EA. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017; 3:841–849. PMID: 27441411.

31. Desjardins A, Sampson JH, Peters KB, Vlahovic G, Randazzo D, Threatt S, et al. Patient survival on the dose escalation phase of the Oncolytic Polio/Rhinovirus Recombinant (PVSRIPO) against WHO grade IV malignant glioma (MG) clinical trial compared to historical controls. J Clin Oncol. 2016; 34(suppl 15):2061. PMID: 27069080.

32. Chiocca EA, Yu J, Phuphanich S, Lukas RV, Kumthekar P, Yang Y, et al. Expanded phase I study of intratumoral Ad-RTS-hIL-12 plus oral veledimex: tolerability and survival in recurrent glioblastoma. J Clin Oncol. 2017; 35(suppl 15):2044. PMID: 28459607.

33. Ostertag D, Cloughesy T, Kalkanis S, Mikkelsen T, Landolfi J, Carter B, et al. ATIM-17. Investigation of anti-tumor cellular immune response elicited by Toca 511 & Toca FC therapy in a recurrent HGG phase 1 trial. Neuro Oncol. 2016; 18(suppl 6):vi21.

34. Huang TT, Hlavaty J, Ostertag D, Espinoza FL, Martin B, Petznek H, et al. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. Cancer Gene Ther. 2013; 20:544–551. PMID: 23969884.

35. Ahmed AU, Thaci B, Tobias AL, Auffinger B, Zhang L, Cheng Y, et al. A preclinical evaluation of neural stem cell-based cell carrier for targeted antiglioma oncolytic virotherapy. J Natl Cancer Inst. 2013; 105:968–977. PMID: 23821758.

36. Ahmed AU, Ulasov IV, Mercer RW, Lesniak MS. Maintaining and loading neural stem cells for delivery of oncolytic adenovirus to brain tumors. Methods Mol Biol. 2012; 797:97–109. PMID: 21948472.

37. Ahmed AU, Thaci B, Alexiades NG, Han Y, Qian S, Liu F, et al. Neural stem cell-based cell carriers enhance therapeutic efficacy of an oncolytic adenovirus in an orthotopic mouse model of human glioblastoma. Mol Ther. 2011; 19:1714–1726. PMID: 21629227.

38. Cloughesy TF, Ostertag D, Landolfi JC, Walbert T, Vogelbaum MA, Elder JB, et al. Durable complete responses observed in IDH1 mutated high grade glioma at first recurrence undergoing treatment with Toca 511 and Toca FC. J Clin Oncol. 2017; 35(Suppl 15):e13504.

39. Hottinger AF, Pacheco P, Stupp R. Tumor treating fields: a novel treatment modality and its use in brain tumors. Neuro Oncol. 2016; 18:1338–1349. PMID: 27664860.

40. Stupp R, Idbaih A, Steinberg DM, Read W, Toms S, Barnett G, et al. LTBK-01: Prospective, multi-center phase III trial of tumor treating fields together with temozolomide compared to temozolomide alone in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(suppl 6):i1. PMID: 26705298.

41. Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015; 314:2535–2543. PMID: 26670971.

42. Reardon DA, Desjardins A, Schuster J, Tran DD, Fink KL, Nabors LB, et al. IMCT-08 ReACT: long-term survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. Neuro Oncol. 2015; 17:v109.

43. Weller M, Butowski M, Trand DD, Recht LD, Lim M, Hirte H, et al. Rindopepimut with temozolomide in patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol. 2017; 18:1373–1385. PMID: 28844499.

44. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015; 373:1627–1639. PMID: 26412456.

45. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015; 372:2521–2532. PMID: 25891173.

46. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014; 515:558–562. PMID: 25428503.

47. Omuro A, Vlahovic G, Baehring J, Butowski NA, Reardon DA, Cloughesy T, et al. ATIM-16. Nivolumab combined with radiotherapy with or without temozolomide in patients with newly diagnosed glioblastoma: results from phase 1 safety cohorts in CHECKMATE 143. Neuro Oncol. 2016; 18(suppl 6):vi21.

48. Reardon DA, Kim TM, Frenel JS, Santoro A, Lopez J, Subramaniam DS, et al. ATIM-35. Results of the phase IB KEYNOTE-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-L1-positive glioblastoma multiforme (GBM). Neuro Oncol. 2016; 18(suppl 6):vi25–vi26.

49. Sahebjam S, Johnstone PA, Forsyth P, Arrington J, Jaglal M, Tran ND, et al. ATIM-15. A phase I trial of hypofractionated stereotactic irradiation (HFSRT) with pembrolizumab and bevacizumab in patients with recurrent high grade gliomas. Neuro Oncol. 2016; 18(suppl 6):vi21.

50. Dixit K, Kumthekar P, Kruser T, Bloch O, Chandler J, Tate M, et al. ATIM-10. Phase I/II trial of radiation therapy, temozolomide and pembrolizumab followed by temozolomide and pembrolizumab in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016; 18(suppl 6):vi19.

51. Reardon DA, Omuroa A, Brandes AA, Rieger J, Wick A, Sepulveda J, et al. OS10.3 Randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143. Neuro-Oncology. 2017; 19(suppl 3):iii21.

52. Reardon D, Kaley T, Dietrich J, Lim M, Dunn G, Gan H, et al. ATIM-04. Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): results for cohort B (dur monotherapy), bevacizumab (bev) naïve patients with recurrent GBM. Neuro Oncol. 2016; 18(suppl 6):vi18.

53. Lukas RV, Rodon J, Shih K, Wong ET, Becker K, Fasso M, et al. Clinical activity and safety of atezolizumab (anti-PDL1) in patients with glioblastoma (GBM). In : 20th Ann Sci Meeting Edu Day Soc Neuro-Oncol; 2015 Nov 19-22; San Antonio, TX. Houston (TX): Society for Neuro-Oncology;2015.

54. Zakharia Y, Colman H, Mott F, Lukas R, Vahanian N, Link C, et al. IMCT-21 Updates on phase 1B/2 combination study of the IDO pathway ihibitor indoximod with temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors. Neuro Oncol. 2015; 17:v112.

55. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, et al. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016; 18:557–564. PMID: 26449250.